Triple threat: radiation and immunotherapy join chemo against pancreatic cancer
NCT ID NCT07336953
First seen Jan 22, 2026 · Last updated Jun 19, 2026 · Updated 21 times
Summary
This Phase III trial tests whether adding targeted radiation (SBRT) and an immunotherapy drug (serplulimab) to standard chemotherapy can help people with advanced pancreatic cancer live longer. About 198 participants who have not had prior treatment will be randomly assigned to receive either the combination or chemo alone. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PDAC - PANCREATIC DUCTAL ADENOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, nab-paclitaxel, serplulimab, and stereotactic body radiation therapy
What this could lead to
If successful, this combination could become a new first-line treatment option that extends survival for people with advanced pancreatic cancer.
What could go wrong
This is an early-stage Phase III trial, so results are not yet known. Adding radiation and immunotherapy may increase side effects without improving outcomes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.